Quest Diagnostics Inc (DGX) Stock Price, Quote & News

Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, go...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 973 520 2700

Website: www.questdiagnostics.com

Address:

500 Plaza Drive, Secaucus, United States

MaxDomain Apr. 18 at 6:59 AM

$MTEN 👀whales accumulating ? biggest comeback happening? watch for next week and coming months! Was at almost 20B marketcap, now around 1.54M, this will rally hard in parabolic mode! $ESAB $TSHA $CVCO $DGX

0 · Reply

Sambong Apr. 16 at 4:20 PM

$DGX a good long candidate with 190 stop

1 · Reply

BreakoutsHappen Apr. 7 at 4:34 PM

VCP Scanner Today: $DGX $UNF https://breakoutshappen.com/scanners/vcp-scanner

0 · Reply

DavyDaveCharts Mar. 24 at 5:16 PM

$DGX weekly: basing in low 190s for launch pad to 213.

0 · Reply

OfficialStocktwitsUser Mar. 21 at 12:50 AM

$DGX RSI: 17.05, MACD: -0.5481 Vol: 5.70, MA20: 203.19, MA50: 195.37 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Mar. 10 at 1:08 PM

$DGX poised for growth despite macro headwinds 🚀 Quest Diagnostics' investments in advanced diagnostics and strategic acquisitions show potential, with a 16.5% stock rally in the past year and earnings surprises in each of the last four quarters. However, a debt-laden balance sheet and economic pressures could pose challenges. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2881329/should-you-continue-to-hold-dgx-stock-in-your-portfolio?cid=sm-stocktwits-2-2881329-body-36690&ADID=SYND_STOCKTWITS_TWEET_2_2881329_BODY_36690

0 · Reply

ZacksResearch Mar. 10 at 12:08 PM

$DGX quietly gaining momentum — but is it time to keep holding? Quest Diagnostics is seeing strong gains from physician and hospital channels while also pushing forward with AI-powered solutions, a combination that could strengthen its operational edge and growth narrative. Is DGX still a solid portfolio hold? Discover the full breakdown 👉 https://www.zacks.com/stock/news/2881329/should-you-continue-to-hold-dgx-stock-in-your-portfolio?cid=sm-stocktwits-2-2881329-teaser-36680&ADID=SYND_STOCKTWITS_TWEET_2_2881329_TEASER_36680

0 · Reply

Small_time_trader Feb. 11 at 7:22 PM

$DGX ATH !!! Congrats 🎉 Longs

0 · Reply

erevnon Feb. 11 at 3:13 PM

Barclays maintains Quest Diagnostics $DGX at Overweight and raises the price target from $210 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 11 at 12:12 PM

Jefferies maintains Quest Diagnostics $DGX at Buy and raises the price target from $215 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers

Mar 19, 2026, 10:00 AM EDT - 4 weeks ago

Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026

Mar 12, 2026, 4:07 PM EDT - 5 weeks ago

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

Mar 2, 2026, 9:02 AM EST - 6 weeks ago

Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

Feb 27, 2026, 10:00 AM EST - 7 weeks ago

Digi Power X Graduates to Cboe Canada

Feb 26, 2026, 8:24 AM EST - 7 weeks ago

Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

Feb 25, 2026, 10:00 AM EST - 7 weeks ago

Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference

Feb 10, 2026, 4:34 PM EST - 2 months ago

Quest Diagnostics CEO on using blood testing for Alzheimer's diagnosis

Feb 10, 2026, 8:03 AM EST - 2 months ago

Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand

Feb 10, 2026, 6:47 AM EST - 2 months ago

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

Feb 10, 2026, 6:33 AM EST - 2 months ago

Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

Feb 2, 2026, 8:52 AM EST - 2 months ago

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Jan 21, 2026, 2:35 PM EST - 3 months ago

Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year

Jan 15, 2026, 9:00 AM EST - 3 months ago

Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

Jan 8, 2026, 10:00 AM EST - 3 months ago

Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

Jan 6, 2026, 10:01 AM EST - 3 months ago

Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 5, 2026, 8:58 AM EST - 3 months ago

Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan

Dec 19, 2025, 3:20 PM EST - 4 months ago

Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference

Dec 1, 2025, 8:30 AM EST - 4 months ago

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States

Nov 12, 2025, 12:15 PM EST - 5 months ago

Daily Dividend Report: ADP, Agree Realty, Group 1, DGX, Aflac

ADP ADC AFL GPI

Nov 11, 2025, 4:22 PM EST - 5 months ago

Quest Diagnostics Declares Quarterly Cash Dividend

Nov 3, 2025, 4:09 PM EST - 5 months ago

Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference

Oct 27, 2025, 7:45 AM EDT - 6 months ago

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Oct 22, 2025, 1:19 PM EDT - 6 months ago

Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings

Oct 21, 2025, 7:16 AM EDT - 6 months ago

Quest Diagnostics raises annual profit and revenue forecasts on lab test demand

Oct 21, 2025, 6:45 AM EDT - 6 months ago

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Sep 25, 2025, 10:00 AM EDT - 7 months ago

Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

Sep 24, 2025, 8:05 AM EDT - 7 months ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

Sep 23, 2025, 7:07 AM EDT - 7 months ago

Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

Sep 22, 2025, 8:07 AM EDT - 7 months ago

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

Sep 18, 2025, 9:00 AM EDT - 7 months ago

WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

Sep 15, 2025, 6:21 PM EDT - 7 months ago

Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

Sep 4, 2025, 9:32 AM EDT - 8 months ago

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

Sep 2, 2025, 6:27 AM EDT - 8 months ago

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

Aug 26, 2025, 9:00 AM EDT - 8 months ago

Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan

Aug 25, 2025, 8:52 AM EDT - 8 months ago

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

Aug 15, 2025, 6:14 PM EDT - 8 months ago

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

Aug 7, 2025, 9:08 AM EDT - 9 months ago

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

Aug 5, 2025, 8:33 AM EDT - 9 months ago

Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

Jul 29, 2025, 8:52 AM EDT - 9 months ago

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

PACB

Jul 22, 2025, 1:10 PM EDT - 9 months ago

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Jul 22, 2025, 7:17 AM EDT - 9 months ago

Quest Diagnostics raises annual forecasts on strong diagnostic testing demand

Jul 22, 2025, 6:47 AM EDT - 9 months ago

Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Jul 15, 2025, 7:57 AM EDT - 9 months ago

Quest Diagnostics Introduces Testing for Oropouche Virus

Jul 9, 2025, 8:24 AM EDT - 10 months ago

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease

Jun 25, 2025, 9:07 AM EDT - 10 months ago

Quest Diagnostics Releases 2024 Corporate Responsibility Report

Jun 23, 2025, 10:52 AM EDT - 10 months ago

Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

Jun 10, 2025, 8:03 AM EDT - 11 months ago

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

May 20, 2025, 8:52 AM EDT - 11 months ago

More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

May 16, 2025, 1:11 PM EDT - 1 year ago

Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference

MaxDomain Apr. 18 at 6:59 AM

0 · Reply

Sambong Apr. 16 at 4:20 PM

$DGX a good long candidate with 190 stop

1 · Reply

BreakoutsHappen Apr. 7 at 4:34 PM

VCP Scanner Today: $DGX $UNF https://breakoutshappen.com/scanners/vcp-scanner

0 · Reply

DavyDaveCharts Mar. 24 at 5:16 PM

$DGX weekly: basing in low 190s for launch pad to 213.

0 · Reply

OfficialStocktwitsUser Mar. 21 at 12:50 AM

0 · Reply

ZacksResearch Mar. 10 at 1:08 PM

0 · Reply

ZacksResearch Mar. 10 at 12:08 PM

0 · Reply

Small_time_trader Feb. 11 at 7:22 PM

$DGX ATH !!! Congrats 🎉 Longs

0 · Reply

erevnon Feb. 11 at 3:13 PM

Barclays maintains Quest Diagnostics $DGX at Overweight and raises the price target from $210 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 11 at 12:12 PM

Jefferies maintains Quest Diagnostics $DGX at Buy and raises the price target from $215 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Small_time_trader Feb. 10 at 4:02 PM

$DGX Beat, raise…and oh yeah let’s kick the Div’y up a bit !!

0 · Reply

Small_time_trader Feb. 10 at 3:48 PM

$LH $DGX >> $LH

0 · Reply

topstockalerts Feb. 10 at 3:39 PM

$DGX Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.

0 · Reply

ortega1963 Feb. 10 at 2:54 PM

$DGX nice volume

0 · Reply

ortega1963 Feb. 10 at 2:35 PM

$DGX Long. tight stop loss

0 · Reply

OpenOutcrier Feb. 10 at 1:28 PM

$DGX (+1.4% pre) Quest’s (NYSE:DGX) Q4 CY2025: Beats On Revenue https://ooc.bz/l/92645

0 · Reply

StocktwitsEarnings Feb. 10 at 12:00 PM

$DGX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $2.21 up 11.62% YoY • Reported revenue of $2.81B up 7.06% YoY • Quest Diagnostics expects full year 2026 revenues between $11.7B and $11.82B, with reported diluted EPS between $9.45 and $9.65, and adjusted diluted EPS between $10.50 and $10.70.

0 · Reply

AStrokeOfLuck Feb. 10 at 11:51 AM

$DGX

0 · Reply

ZacksResearch Feb. 9 at 8:10 PM

MedTech earnings week: What to watch for $DGX, $ZBH, & $EW 🚑 🔍 $DGX expected to rise 5.4% in EPS, but no Earnings ESP edge 🦾 $ZBH's Hips & Knees businesses might see growth, with revenue expected to rise 💉 $EW's performance in TAVR and Surgical Structural Heart could contribute to growth See the full earnings preview here 👉 https://www.zacks.com/stock/news/2842431/medtech-stocks-to-report-earnings-on-feb-10-dgx-zbh-ew?cid=sm-stocktwits-2-2842431-body-32715&ADID=SYND_STOCKTWITS_TWEET_2_2842431_BODY_32715

0 · Reply

ZacksResearch Feb. 9 at 7:10 PM

$DGX, $ZBH & $EW set to report earnings Feb. 10 💉 Medtech Q4 shows solid revenue growth, though profits are softer and macro pressures remain a headwind. See the full preview here 👉 https://www.zacks.com/stock/news/2842431/medtech-stocks-to-report-earnings-on-feb-10-dgx-zbh-ew?cid=sm-stocktwits-2-2842431-teaser-32713&ADID=SYND_STOCKTWITS_TWEET_2_2842431_TEASER_32713

0 · Reply

ZacksResearch Feb. 6 at 3:25 PM

$DGX poised for Q4 growth? 🚀 Zacks Consensus Estimate for revenue suggests a 4.8% rise from the year-ago reported figure, with strong DIS business performance and strategic acquisitions boosting physician channels. See if DGX can maintain its earnings streak here 👉 https://www.zacks.com/stock/news/2836553/heres-how-quest-diagnostics-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2836553-body-32313&ADID=SYND_STOCKTWITS_TWEET_2_2836553_BODY_32313

0 · Reply

ZacksResearch Feb. 6 at 2:25 PM

$DGX positioned for a strong Q4 — are expectations too low? 👀 Heading into earnings, revenue and EPS growth are expected, boosted by DIS momentum and benefits from Fresenius assets and consumer testing. Full pre-earnings breakdown here 👉 https://www.zacks.com/stock/news/2836553/heres-how-quest-diagnostics-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2836553-teaser-32312&ADID=SYND_STOCKTWITS_TWEET_2_2836553_TEASER_32312

0 · Reply

Market Cap	21.19B
Revenue (ttm)	11.04B
Net Income (ttm)	992.00M
EPS (ttm)	N/A
PE Ratio	19.43
Forward PE	18.06
Profit Margin	8.99%
Debt to Equity Ratio	0.79

Volume	1,000,000
Avg Vol	948,500
Day's Range	N/A - N/A
Shares Out	110.69M
Stochastic %K	47%
Beta	0.66
Analysts	Sell
Price Target	$218.24